Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents

被引：24

作者：

Credito, K ^{[1
]}

Lin, GR ^{[1
]}

Ednie, LM ^{[1
]}

Appelbaum, PC ^{[1
]}

机构：

[1] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 10期

关键词：

D O I：

10.1128/AAC.48.10.4033-4036.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The MICs of LBM415, a new peptide diformylase inhibitor, were less than or equal to0.06 to 4.0 mug/ml for 258 isolates of Staphylococcus aureus and coagulase-negative staphylococci. LBM415 MICs were similar irrespective of whether the strains were methicillin susceptible or resistant. All strains were also susceptible to vancomycin, linezolid, ranbezolid, daptomycin, oritavancin, and quinupristin-dalfopristin. LBM415 at the MIC was bacteriostatic after 24 h.

引用

页码：4033 / 4036

页数：4

共 24 条

[1] Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor [J].

Anderegg, TR ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 48 (01) :55-57

[2] Quality control guidelines for MIC susceptibility testing of NVPPDF-713: a novel peptide deformylase inhibitor [J].

Anderegg, TR ;

Biedenbach, DJ ;

Jones, RN .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (01) :84-86

[3] In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide [J].

Biavasco, F ;

Vignaroli, C ;

Lupidi, R ;

Manso, E ;

Facinelli, B ;

Varaldo, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2165-2172

[4] In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].

Boucher, HW ;

Wennersten, CB ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229

[5] Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center [J].

Bozdogan, B ;

Esel, D ;

Whitener, C ;

Browne, FA ;

Appelbaum, PC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (05) :864-868

[6] In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates [J].

Cercenado, E ;

García-Garrote, F ;

Bouza, E .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (01) :77-81

[7] In vitro activity of linezolid against staphylococci [J].

Cuny, C ;

Witte, W .

CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (06) :331-333

[8] Oxazolidinones - A review [J].

Diekema, DJ ;

Jones, RN .

DRUGS, 2000, 59 (01) :7-16

[9]

FRITSCHE TR, IN PRESS CLIN MICROB

[10] Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid [J].

Henwood, CJ ;

Livermore, DM ;

Johnson, AP ;

James, D ;

Warner, M ;

Gardiner, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :931-940

← 1 2 3 →